Literature DB >> 33777742

Circular RNA CHST15 Sponges miR-155-5p and miR-194-5p to Promote the Immune Escape of Lung Cancer Cells Mediated by PD-L1.

Jianru Yang1, Yang Jia2, Bing Wang3, Shengrong Yang3, Kun Du3, Yujie Luo3, Yunhe Li3, Bing Zhu3.   

Abstract

BACKGROUND: The effects of up-regulated CircCHST15 on lung cancer remained unclear. In this study, the role of CircCHST15 in lung cancer was investigated.
METHODS: Dual-luciferase reporter verified the bioinformatics prediction that CircCHST15 targeted miR-155-5p and miR-194-5p. The correlation between CircCHST15 and PD-L1 was analyzed by Pearson analysis. CCK-8 and colony formation was performed to determine the viability and proliferation of lung cancer cells. After the lung cancer (subcutaneous-xenotransplant) model was established in mice, the T cell subtype and related cytokines in mouse tumor tissues were detected by flow cytometry and ELISA. Moreover, the expressions of CircCHST15, miR-155-5p, miR-194-5p, immune-related, and proliferation-related factors of the lung cancer cells or mice tumor tissues were detected by immunohistochemistry, RT-qPCR, or Western blot.
RESULTS: CircCHST15 and PD-L1 were high-expressed in lung cancer, and the two was positively correlated. CircCHST15 targeted miR-155-5p and miR-194-5p, the later further targeted PD-L1. Lung cancer cell viability and proliferation were increased by miR-155-5p and inhibited by miR-194-5p. CircCHST15 located in the cytoplasm promoted tumor growth, down-regulated the expressions of miR-155-5p and miR-194-5p, and up-regulated the expressions of PD-L1, Ki-67, PCNA, CCL17, CCL22, IFN-γ, TNF-β, and IL-10. Also, CircCHST15 decreased the CD8+ cells in mouse blood and tumor, but increased the Tregs in mouse tumor. PD-L1 inhibitor showed an opposite effect to CircCHST15 on mouse tumors.
CONCLUSION: CircCHST15 sponged miR-155-5p and miR-194-5p to promote the PD-L1-mediated immune escape of lung cancer cells.
Copyright © 2021 Yang, Jia, Wang, Yang, Du, Luo, Li and Zhu.

Entities:  

Keywords:  CircCHST15; PD-L1; immune escape; lung cancer; miR-155-5p; miR-194-5p

Year:  2021        PMID: 33777742      PMCID: PMC7991744          DOI: 10.3389/fonc.2021.595609

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  41 in total

1.  The SOX2OT/miR-194-5p axis regulates cell proliferation and mobility of gastric cancer through suppressing epithelial-mesenchymal transition.

Authors:  Ruqiong Wei; Can Ding; Raquel Alarcòn Rodrìguez; Marìa Del Mar Requena Mullor
Journal:  Oncol Lett       Date:  2018-09-12       Impact factor: 2.967

2.  miR-155-5p antagonizes the apoptotic effect of bufalin in triple-negative breast cancer cells.

Authors:  Qian Wang; Ce Li; Zhitu Zhu; Yuee Teng; Xiaofang Che; Yan Wang; Yanju Ma; Yiding Wang; Huachuan Zheng; Yunpeng Liu; Xiujuan Qu
Journal:  Anticancer Drugs       Date:  2016-01       Impact factor: 2.248

3.  Bronchial Artery Embolization for Hemoptysis in Primary Lung Cancer: A Retrospective Review of 84 Patients.

Authors:  Kichang Han; Ki Woong Yoon; Jin Hyoung Kim; Gyoung Min Kim
Journal:  J Vasc Interv Radiol       Date:  2019-03       Impact factor: 3.464

4.  A circRNA derived from linear HIPK3 relieves the neuronal cell apoptosis in spinal cord injury via ceRNA pattern.

Authors:  Jingwei Zhao; Xi Qi; Jingyu Bai; Xiang Gao; Liming Cheng
Journal:  Biochem Biophys Res Commun       Date:  2020-04-02       Impact factor: 3.575

Review 5.  Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints.

Authors:  Niki Karachaliou; Maria Gonzalez Cao; Cristina Teixidó; Santiago Viteri; Daniela Morales-Espinosa; Mariacarmela Santarpia; Rafael Rosell
Journal:  Cancer Biol Med       Date:  2015-06       Impact factor: 4.248

6.  Detection of miR-155-5p and imaging lung cancer for early diagnosis: in vitro and in vivo study.

Authors:  Hai-Zhen Zhu; Chun-Ju Fang; Yi Guo; Qi Zhang; Li-Min Huang; Dong Qiu; Guang-Peng Chen; Xiu-Feng Pang; Jian-Jun Hu; Jian-Guo Sun; Zheng-Tang Chen
Journal:  J Cancer Res Clin Oncol       Date:  2020-05-23       Impact factor: 4.553

7.  Circular RNA hsa_circ_0008305 (circPTK2) inhibits TGF-β-induced epithelial-mesenchymal transition and metastasis by controlling TIF1γ in non-small cell lung cancer.

Authors:  Longqiang Wang; Xin Tong; Zhengyu Zhou; Shengjie Wang; Zhe Lei; Tianze Zhang; Zeyi Liu; Yuanyuan Zeng; Chang Li; Jun Zhao; Zhiyue Su; Cuijuan Zhang; Xia Liu; Guangquan Xu; Hong-Tao Zhang
Journal:  Mol Cancer       Date:  2018-09-27       Impact factor: 27.401

8.  Downregulation of miR-194-5p induces paclitaxel resistance in ovarian cancer cells by altering MDM2 expression.

Authors:  Koji Nakamura; Kenjiro Sawada; Mayuko Miyamoto; Yasuto Kinose; Akihiko Yoshimura; Kyoso Ishida; Masaki Kobayashi; Aasa Shimizu; Erika Nakatsuka; Kae Hashimoto; Seiji Mabuchi; Tadashi Kimura
Journal:  Oncotarget       Date:  2019-01-18

9.  Hsa_circ_RNA_0011780 Represses the Proliferation and Metastasis of Non-Small Cell Lung Cancer by Decreasing FBXW7 via Targeting miR-544a.

Authors:  Yong Liu; Chuanping Yang; Chengsong Cao; Qing Li; Xin Jin; Hanping Shi
Journal:  Onco Targets Ther       Date:  2020-01-23       Impact factor: 4.147

Review 10.  Advances in Research on the circRNA-miRNA-mRNA Network in Coronary Heart Disease Treated with Traditional Chinese Medicine.

Authors:  Fei Lin; Heng-Wen Chen; Guo-An Zhao; Yan Li; Xuan-Hui He; Wan-Qian Liang; Zhuo-Lin Shi; Si-Yu Sun; Pan-Pan Tian; Ming-Yan Huang; Chao Liu
Journal:  Evid Based Complement Alternat Med       Date:  2020-02-17       Impact factor: 2.629

View more
  8 in total

1.  Circular RNA hsa_circ_0000190 Facilitates the Tumorigenesis and Immune Evasion by Upregulating the Expression of Soluble PD-L1 in Non-Small-Cell Lung Cancer.

Authors:  Yung-Hung Luo; Yi-Ping Yang; Chian-Shiu Chien; Aliaksandr A Yarmishyn; Afeez Adekunle Ishola; Yueh Chien; Yuh-Min Chen; Ping-Hsing Tsai; Tzu-Wei Lin; Mong-Lien Wang; Shih-Hwa Chiou
Journal:  Int J Mol Sci       Date:  2021-12-22       Impact factor: 5.923

2.  microRNA-194 is increased in polycystic ovary syndrome granulosa cell and induce KGN cells apoptosis by direct targeting heparin-binding EGF-like growth factor.

Authors:  Yi-Xuan Wu; Yan-Shan Lin; Si-Chen Li; Xi Yao; Mingwei Cheng; Lin Zhu; Hai-Ying Liu
Journal:  Reprod Biol Endocrinol       Date:  2021-11-23       Impact factor: 5.211

3.  [Research Progress of Circular RNAs in Tumor Immunotherapy].

Authors:  Chenyu Zhang; Lei Peng; Jingbin Ji; Wenjie Jiao
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2021-10-11

4.  Exosomal circSHKBP1 participates in non-small cell lung cancer progression through PKM2-mediated glycolysis.

Authors:  Wenbiao Chen; Donge Tang; Junqi Lin; Xiaoming Huang; Shaoming Lin; Guanle Shen; Yong Dai
Journal:  Mol Ther Oncolytics       Date:  2022-02-02       Impact factor: 7.200

Review 5.  Role of Circular RNAs in the Regulation of Immune Cells in Response to Cancer Therapies.

Authors:  Ángeles Carlos-Reyes; Susana Romero-Garcia; Estefania Contreras-Sanzón; Víctor Ruiz; Heriberto Prado-Garcia
Journal:  Front Genet       Date:  2022-02-02       Impact factor: 4.599

Review 6.  Oxidative Stress and Inflammation in Cardiovascular Diseases and Cancer: Role of Non-coding RNAs.

Authors:  Pieterjan Ginckels; Paul Holvoet
Journal:  Yale J Biol Med       Date:  2022-03-31

Review 7.  Role of circular RNAs in the diagnosis, regulation of drug resistance and prognosis of lung cancer.

Authors:  Chengpeng Sang; Dingyu Rao; Caixia Wu; Yao Xia; Maoyan Si; Zhixian Tang
Journal:  Oncol Lett       Date:  2022-07-07       Impact factor: 3.111

8.  Digital multiplexed analysis of circular RNAs in FFPE and fresh non-small cell lung cancer specimens.

Authors:  Carlos Pedraz-Valdunciel; Stavros Giannoukakos; Nicolas Potie; Ana Giménez-Capitán; Chung-Ying Huang; Michael Hackenberg; Alberto Fernandez-Hilario; Jill Bracht; Martyna Filipska; Erika Aldeguer; Sonia Rodríguez; Trever G Bivona; Sarah Warren; Cristina Aguado; Masaoki Ito; Andrés Aguilar-Hernández; Miguel Angel Molina-Vila; Rafael Rosell
Journal:  Mol Oncol       Date:  2022-02-10       Impact factor: 7.449

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.